Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CELGZ - Celgene Corporation Contingent Value Rights 2010-2011

Previous close
0.4404
0.440   100.000%

Share volume: 0
Last Updated: Fri 29 Nov 2019 07:00:01 PM CET
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
59%
Profitability 75%
Dept financing 25%
Liquidity 0%
Performance 65%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.44
P/E Ratio 
N/A
DAY RANGE
$0.44 - $0.44
EPS 
$0.00
52 WEEK RANGE
$0.11 - $2.65
52 WEEK CHANGE
$59.32
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
$0.0359
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$23,850
AVERAGE 30 VOLUME 
$34,360
Company detail
CEO:
Region: US
Website: http://www.celgene.com
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Recent news